The expression level of pd-l1 (CD274) mrna in peripheral blood is a potential biomarker for predicting recurrence in breast cancer

Takaaki Masuda, Miwa Noda, Akihiro Kitagawa, Qingjiang Hu, Atsushi Fujii, Shuhei Ito, Keisuke Kosai, Yuki Ando, Yoshihiro Matsumoto, Hajime Ohtsu, Hiroki Uchida, Shinji Ohno, Koshi Mimori

Research output: Contribution to journalArticle

Abstract

Background/Aim: Programmed death-ligand 1 (PD-L1/CD274) elicits T-cell anergy, leading to immune suppression. We aimed to determine the prognostic relevance of PD-L1 expression in the blood of breast cancer (BC) patients. Materials and Methods: We measured PD-L1 mRNA expression in blood and tumor tissues of BC patients using RT-qPCR and a dataset from The Cancer Genome Atlas, and performed a survival analysis of PD-L1 expression in the blood of 330 BC patients. Flow cytometric analysis was performed using blood cells. Results: No statistical difference in PD-L1 expression was seen between normal controls and BC in blood or tissues. There was a significant positive correlation between the PD-L1 expression levels in blood and tissues. Decreased PD-L1 expression in blood or tissues was associated with poor recurrence-free survival. PD-L1 is mainly expressed in polymorphonuclear leukocytes. Conclusion: Low expression of PD-L1 in the blood could serve as a biomarker of poor prognosis in BC patients.

Original languageEnglish
Pages (from-to)3733-3742
Number of pages10
JournalAnticancer research
Volume40
Issue number7
DOIs
Publication statusPublished - Jul 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The expression level of pd-l1 (CD274) mrna in peripheral blood is a potential biomarker for predicting recurrence in breast cancer'. Together they form a unique fingerprint.

  • Cite this